We hereby announce that there has been a change in our company’s management structure.
As of March 31, 2025, Mr. Iku Sugioka has stepped down from his position as CEO, and Mr. Masahiko Kato has resigned from his position as Director. We are pleased to announce that Mr. Yasushi Matsuoka has been appointed as the new CEO effective April 1, 2025.
We would like to inform you of the development of the regenerative medicine cell product “AE101” (indication: bullous keratopathy) in the Chinese region (mainland China, Hong Kong, Macau, and Taiwan) and South Korea as follows:
ActualEyes Inc. announces the implementation of Series C financing by a domestic pharmaceutical company, bringing its accumulated fundraising to 850 million JPY. The Series C round is ongoing and expected to reach 1 billion JPY upon completion.
We are pleased to inform you that the first patient in our domestic Phase II clinical trial of AE101, a regenerative medicine cell product under development by ActualEyes Inc., has successfully received the transplantation. AE101 is designed for the treatment of bullous keratopathy (see Note 1). We are also pleased to report that the necessary safety evaluations have been completed, allowing for the continuation of the trial with subsequent patients.
ActualEyes Inc. is pleased to announce the submission of the Phase II clinical trial protocol for “AE101,” a cutting-edge therapy for the treatment of bullous keratopathy, to the Pharmaceuticals and Medical Devices Agency (PMDA). After PMDA’s 30-day investigation of the clinical trial protocol, we anticipate commencing the clinical trial.
This website uses cookies for the purpose of operating our services and improving the user experience. For details, please refer to our privacy policy. By clicking on the “Agree” button or continuing to use our website, you will be regarded as having agreed to our use of cookies.